RecruitingPhase 4NCT06928753

Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion

Studying Chikungunya

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Centre Hospitalier Universitaire de la Réunion
Principal Investigator
Patrick GERARDIN, MD
CHU La Réunion
Intervention
IXCHIQ(biological)
Enrollment
1800 enrolled
Eligibility
18 years · All sexes
Timeline
2025 – 2026

Study locations (1)

Collaborators

ANRS, Emerging Infectious Diseases · Région La Réunion · ARS La Réunion · Direction Générale de l'offre de Soins (DGOS)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06928753 on ClinicalTrials.gov

Other trials for Chikungunya

Additional recruiting or active studies for the same condition.

See all trials for Chikungunya →

← Back to all trials